Overview / Abstract: |
Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, as well as discuss emerging therapies and monitoring strategies for patient care. Start the activity now! STATEMENT OF NEED Tumor lysis syndrome is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream (Baudon et al, 2016). This release of intracellular materials results in severe metabolic abnormalities such as hyperuricemia and hyperphosphatemia, which may cause acute renal injury, and hypokalemia and hypocalcemia, which may cause seizures, neuromuscular symptoms, and cardiac arrhythmias (Howard et al, 2016; Baudon et al, 2016). The occurrence of TLS may prevent or delay the administration of potentially life-saving chemotherapy (Dinnel et al, 2015). Furthermore, the kidney damage, heart failure, fluid retention, and neuromuscular and gastrointestinal effects caused by TLS may lead to reductions in chemotherapy dosing and alter the selection of cytotoxic agents (McBride & Westervelt, 2012). The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected (Baudon et al, 2016). The overall mortality rate of patients with TLS is 15% (Jones et al, 2015). TARGET AUDIENCE Hematologist/oncologists, physician assistants, nurse practitioners, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: Assess the risk for TLS associated with emerging therapies for hematologic malignancies |
Expiration |
Sep 30, 2022 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ANCC |
Presenters / Authors / Faculty |
Matthew S. Davids, MD, MMSc |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy |
Keywords / Search Terms |
i3 Health i3 Health i3 Health oncology, i3 Health, CNE, NCPD, free CNE, free NCPD Free CE CME Free CE CME, tumor lysis syndrome, TLS Free CE CME |